Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Satralizumab Long-Term Safety and Efficacy in NMOSD (SAkuraMoon)
NCT04660539Phase 3Completed
- Sponsor
- Roche
- Start
- Mar 2021
- Primary completion
- May 2024
- Modality
- Monoclonal Antibodies
- Countries
- 18
01
Overview
Phase 3, open-label, single-arm trial of satralizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD), sponsored by Roche. Primary endpoints: Number of Participants With Adverse Events and Serious Adverse Events up to 523 weeks and Number of Participants With Adverse Events of Special Interest up to 523 weeks. Started Mar 2021; status: completed.
02
Drugs
satralizumab
03
Conditions
Neuromyelitis Optica Spectrum Disorder (NMOSD)
Beyond the preview
Go deeper on NCT04660539.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04660539.